Before it undertakes a good manufacturing inspection, the UK Medicines and Healthcare Products Regulatory Agency is now asking drug manufacturers to declare whether they have a policy on data integrity/governance. The manufacturer's response on this front, besides other issues, will help the MHRA decide on how frequently the site should be inspected.
Information on a company's data integrity policy is being sought through a revised form – the pre-inspection planning report1 –...




